<SEC-DOCUMENT>0001193125-12-176244.txt : 20120423
<SEC-HEADER>0001193125-12-176244.hdr.sgml : 20120423
<ACCEPTANCE-DATETIME>20120423172626
ACCESSION NUMBER:		0001193125-12-176244
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120420
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120423
DATE AS OF CHANGE:		20120423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		12774096

	BUSINESS ADDRESS:	
		STREET 1:		10813 S. RIVER FRONT PARKWAY
		STREET 2:		STE. 500
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		10813 S. RIVER FRONT PARKWAY
		STREET 2:		STE. 500
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d339315d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): April&nbsp;20, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Lifevantage Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Colorado</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-30489</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90-0224471</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9815 S. Monroe Street, Suite 100, Sandy, UT</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>84070</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;432-9000 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
April&nbsp;20, 2012, Lifevantage Corporation issued a press release. A copy of the press release is attached as Exhibit 99.1. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release issued on April 20, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April&nbsp;20, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lifevantage Corporation</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Carrie E. McQueen </FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Carrie E. McQueen</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer &amp; Treasurer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d339315dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g339315g31h34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LifeVantage Corporation Makes Charitable Donation To Traffic Jam </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Salt Lake City, UT, April&nbsp;20, 2012</B>, LifeVantage Corporation (OTCBB: LFVN), maker of Protandim<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2 Synergizer&#153; patented dietary supplement, announced today it has made a substantial charitable
donation to Traffic Jam Campaign, a non-profit organization dedicated to freeing children around the world from child trafficking for the purposes of slavery, prostitution and conscripted military service. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Traffic Jam Campaign was founded by Paul Myhill, who also co-founded the predecessor company of LifeVantage Corporation in 2004. In 2006, Mr.&nbsp;Myhill
stepped down from all his roles with the Company to focus on charitable endeavors and the Company generously gifted stock to a foundation under Mr.&nbsp;Myhill&#146;s trusteeship. In 2011, LifeVantage and many of its Independent Distributors again
contributed to Mr.&nbsp;Myhill&#146;s charitable organization. Although in recent months, Mr.&nbsp;Myhill&#146;s communications in various social media forums created misunderstandings regarding the Company, LifeVantage and Mr.&nbsp;Myhill are
pleased to announce that all areas of misunderstanding have been amicably resolved in full. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are pleased to make this significant
contribution to Traffic Jam Campaign, an organization that is dedicated to improving the lives of children,&#148; said Douglas C. Robinson, President and CEO of LifeVantage. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;I express my gratitude to LifeVantage for today&#146;s generous contribution as well as its past contributions to further the mission of Traffic Jam Campaign, and I deeply regret any damage or
confusion that may have been caused by my public remarks in recent months,&#148; Paul Myhill said. &#147;I fully support LifeVantage and its mission, its corporate integrity, its marketing strategy and efforts, and its continued dedication to
improving the quality of life for others. I recognize and appreciate the extensive contributions of Dr.&nbsp;Joe McCord and others in the Company in developing, testing and refining Protandim and acknowledge that credit for the current success of
LifeVantage and Protandim belongs to many. I am honored to continue as a champion of LifeVantage, but remain primarily focused on my efforts toward helping children around the world.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Robinson continued, &#147;Mr. Myhill shares our commitment to improving the lives of others and we are pleased to have resolved all of his concerns. LifeVantage remains dedicated to offering
science based, research backed products that result in a better quality of life for all. Our flagship product Protandim has been reviewed and validated by investigators at highly respected universities and institutions and continues to be studied
worldwide for its ability to reduce oxidative stress, primarily through the activation of Nrf2. We also remain committed to conducting our business, as always, with the highest degree of integrity and transparency.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Myhill is not a member of LifeVantage management and is not a spokesperson for the Company. All inquiries regarding LifeVantage and Protandim
should be directed to the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About LifeVantage Corporation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">LifeVantage, (OTCBB:LFVN), maker of Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2 Synergizer&#153; patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that looks to
transform wellness and anti-aging internally and externally with products that </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g339315g31h34.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 with corporate headquarters in Salt Lake City, UT and operations in San Diego, CA. For more
information, visit www.LifeVantage.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as words such as &#147;believe,&#148; &#147;hopes,&#148; &#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148;
&#147;anticipates,&#148; &#147;look forward to&#148; and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not
limited to, statements we make regarding our anticipated revenue, operating profitability, cash flow from operations and future investment and growth. Such forward-looking statements are not guarantees of performance and the Company&#146;s actual
results could differ materially from those contained in such statements. These forward-looking statements are based on the Company&#146;s current expectations and beliefs concerning future events affecting the Company and involve known and unknown
risks and uncertainties that may cause the Company&#146;s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the potential failure or unintended
negative consequences of the implementation of the Company&#146;s network marketing sales channel; the Company&#146;s ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the potential for third
party and governmental actions involving the Company&#146;s network marketing sales channel; the potential for product liability claims against the Company; the risk that government regulators and regulations could adversely affect the
Company&#146;s business; future laws or regulations may hinder or prohibit the production or sale of the Company&#146;s existing product and any future products; unfavorable publicity could materially hurt the Company&#146;s business; and the
Company&#146;s ability to protect its intellectual property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q
under the caption &#147;Risk Factors,&#148; and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements
contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this document, except as required by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cindy England 801.432.9036 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor
Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">-or- </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Mills
310.954.1105 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Managing Director, ICR, LLC </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Media Relations Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrea Ramsey 801.432.9019 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g339315g31h34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g339315g31h34.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+P#A`P$1``(1`0,1`?_$`+P```(!!`(#````````
M``````@)"@`"`P<!!@0%"P$``00#`0``````````````!0,$!@<``0(($```
M!0,#`@,$!@4("P`````!`@,$!08'"``1$B$),4$342(4"F&!0B,5%O!QD:$7
ML='A,E)B<I+!@J+2,T-3)#15&1$``0(%`@0"!P4$"`<``````0(#`!$A!`4Q
M$D%1809Q$X&1H;$B,A3PP='A4D)B(Q7Q@J*RTB06!W+",U-S-"7_V@`,`P$`
M`A$#$0`_`)^(AU']8_RZY*UIU%(S8E0E%G/B.P;_`+`THE0690D4!OXN$<\N
M?7K_`&=<N)G\''6.FETWGG*/&7'@`=#<MQX&`-P((EV`ZA?,A1'?]>D[="DO
M!)TKQZ1NY6DL%<^7OB`)WC.[#F==;.JJL0,0:]N#1-,4-5C.VL6SM--2<%6M
M:URB(-Y(6\E%+-G"4?ZAAW%14B1=O;J]NV>V\9;69O<VE/EE!GN0E=9S(T)D
M!%'YSN&[=N1:8]:@^E0E)2DT(E7K/3UPWCL(V][J5M[OWWA,_P"8O7+40XH2
MEGMO5+JW`5N`T)4BLI(#.(Q4F>:F0(Y2:^GZJ?,!+[-13O![M$M^5@PU]3N'
MRM;-"9UV@&DN-8E?:B.XE*#V6+AMR#\SF[]D2I,_E$H@1$A>0>6X@&_CJM7W
MFDF1D7N`(X^,60A"%J26:-SK(2BBK<B^]N7?H/@/L^O6)<&S<Z`/;'3[*R)-
M&OJBXIBFZ`/+;QZ?T:06_;NG8D`^C\H0#3[8FHJ]<<BK[=^GT!Y:=%00FL=A
M(7%`H'EO]0!KE#H7&RSLBN8#U_3^36U*;29+EN\(X\MQ54$A,5Z@%Z;C^GU:
MUYC'3U1L,/GB8QF/RVZCT_TZ[0ZR)R]QAO<6[Y*=3KRC(*OAMOT#Z-<&:Q\'
M$P\;&U'QZ_;E%AU`VY=0,'T!Y[>>F^U]KXE?(.L<H#2GP$_-7ATBA-N`AU]O
M@'T^6GRD;D@0DRI*5JZ"%Z6=S7/<_/7)K#,:33CFV/5O;?5HE50+B=2;5J^1
M!@9LHF)QX>CY=`T1>L`U8-.UFK_#.!K>4W7[C9X3Y\P/OAAGK!_>_=H#YK?)
M/J@QY#O,^R.>8#UW'K^GLUGF-<D^J./IU\SZXY]0`]H_LZ_MTY'_`$MZ=(U(
M3\LZB*]0H>`?N#3=IQ2G)'[5C?E`5E[HX%;C[>O7R^C7=PORU"@-(5:`<!EP
MBO5`V_+<-NOZ;!I--TA)DH`>N,7;J.A,6BH7[(CX_N^L-*BXME_"2#Z#""K:
MX_9)UYB./5*("'7<?8`:Q'TC:MR0D'P_*%W+=Q;>PDB+2G*4?/<1V\`\QTNI
M]O2?OANWC]DU3,_1&<=9)"QP,)_Q6=-/&,VP>P-<R$+3/,Q$SL!W[KYW;[J+
M7!*8M70\71:N1EU[.DJ6->OU)=:*H&;J5BQ?N"+/542.WC>+*8X`4`Y;@`!J
MP,EVPBUPK>1E+<RA1J#\R9Z2BO<=W,7\P[8ZE+ZT@2/!4M9Q*](8#$*(%X=`
M#CN)N(AT$.0]1ZAJOB/*>EP_*+#0L/,A?.!NR_O')X]8RWTOA"L&\K+VLMC5
ME9Q<:[,H1L[=PL8N](FL*1R&$H^C[=/\4P;S--VA^18`]L#,L_\`0X=;_$$_
MW2?NA,'9%[PUV.YU55[*>N1;^FZ'1ME2<-4+$U/+.EQE/Q5\D@<SHSIRX](Z
M&X`!2\2B!AZ:D_<F#1B'&R!+?,"L^/@(C/;V;.596W.93+@>1/$F(=5R\DI+
M$ONYWCR-B*;85C*6SR'K:4CJ;E$CKIS#HCY<R:.Q#`H8P&\^H@&KDL[!O-X!
M%H2H`%<]IVF1IK6*BN;@XO/+?6$U2B4Q,3UK$QSM(]ZRL^X75]^XBYULJ;LK
M2=EZ"B:P6J--9\#?T7[N0(^=.5I%P=$B+5JUYJ&Z;<MQ\=5-W-V3;XA?FVZW
M5K*I;2M)J21221RBUNW>ZEY!D-/)0EM(U"2#1(YF%ZYQ_,]3T-<^H+0X.VU8
MUTE3[Y>/7N!42+V0),/(]?X=<\-&QJS8%H]82CP,!C"8>N^BV!['M+ICZ_)$
M^6T-R@DID1,C0I)Y<8'9SNA^T?\`H;"2G'#(;IZR!U!$M3PC7&+/S15TX*Z,
M-1F9UI6471,[)HLG]51,?)0\[21W9TVP.5XEVNJ1Q&-_5]10P@`^F4?>#QT3
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M4=T%8*7?0"CI@R!)4Q6JDFP,0JI`,4>@ZEBL*PI26PN3Q!)G(R`D`0)#4F40
M]>:N$J)0D%L2EKKZX']+N7=TRX+,]76J[7-6Q]#+M@=Q"U>S$@QJ:2;*J&53
M<-HTD>U*5!9AZ?$!(804Y=?(%EXK#(7Y:W)+Y$I_"$TYC)E.Y*!M'17XP5&#
MO=1I3*"XU1X]W8ME6.-F4E-QY)5[:"X*"C<)R.2.HBYD*4>KH,E7Z?-$.10`
M_`I@'?KIAE,&A"`[;DEE(^+28TZ5'H@OB,RI8<^J$C24@3SGJ8]OD)W3;8XS
MY2578:ZL8>GZ3I3'Y]>]S6J*AG3V2>IU'3M-QM$1,<(@#B8EG4WNF4.0B5,=
MB^>N+3#J4P'!4JTF::RGI/2NL(7>90ISRTSIT/X^CI`@J]Q;NN7.8FN%C[VV
M@7L\[*9]$?Q)J62AZ^G(7ES0<1L0F@T`RLFU,!DPX&X[]-*W^/L$L%'F$74A
M0D"=1TCNQNKE#@N")M`]3KI!I=O[N847FDI6EM:GHF?L9D;:4Y6UT+)UL15K
M-1)2G$GXG&&<%;.'T=R)RY@3H`AN([ZYO,:NU"7-4J]8,M--##*URB;A:T"A
M`ZZ3\>$)PJ:_V1>/G>ISNG\>,6ZNR?FJFLS:2(GXFDWX,QI>,922;UG(N2DC
MWIC"LLH)0$WB(]-&W&[9>)9-P9`!,N%2)2]7N@(EY\Y1T-3G-0/@#/W@5AV>
M%V5V5U_9NM([(C#*L\88NGHQD]AY*IEW3Q.I':X*"X0:',T9@)DN(>Z7KUT`
M>L<>$`VZ]SA4`*I]/#ASB6)R&0F0M*1(3X^CCQ@0[C]V')2J;BUU;'#3`B[U
MY5J!J-_34Q<&K6KVE*,/*0S]Q&2*#$QXY87#8CAJ8$U`6]\@@;STX&(L4(F^
MLCPD![H3.3OR?A2CV_C'2(OO(9`6`K6GH+N'855?CI1-63;&%C;OT^\=3]"1
MKN56(W:(2KMRR]-N7XA3WC"J&W77#F-96U.U5N1X@CTRA)G*.?5E#HDN=:'E
MPKI#XUK@THA1);AGJ&,_)(T^:K%*M*ND6%3IPK/\0_%%'1CF1*BHTZ@.^W30
MIJUW.;)?&#*7$G\M3T@W<7@0SNX2G[/MZ80[47>"R&R`JV>@>VMB#/Y%T72L
MHO#2=X:E7?0EN7TBV4,5=&.?-T0^)2V*.QRK^6I/:8C%A@N9592Y,`$$2TZC
M7[2B&767R"WMF/2"BLYSG/T&.V6[[M]X[:U_3%L>XCBS5&,"M;2)(:EKNQ?Q
M<M:0DT[^[0CI:8=MP3CDU1,7991<P`)O#7-SVW87#>_'KW#J17P,J&%[7N2_
M95MNDIF.BJ>V#@P9SE:9E/,DD&E*)0+:P-ZI:T;5^R>&?-*L!G'M9).>8.-Q
M3.T?(.RF3X[@`#XZ`Y3MMNS2A0*AN)XC02Z#G!FQ[D5=.*:(&^4]#P],"MDU
MW7:CA+WSN+6$-CZARSOY3/PBE:?A2PM+=4`NN`G^#FZC9M7*9'J:"1P52,<O
M`P;;;]=.&.WD-L?4/J*42G4BGC2&;W<=RM\,,)253EHJOMC31>[3E]C34D*M
MW&<)GEF+0SLPSBT[W6R>2E4T;2)Y-PDV:$JD[@%DVZGJ*[G.*I"E*`CMTT3M
M<%8WK#B;=PEY*"=4D=)TG6!MSG\I;W+9=0D-%8G16DZRK6D/LI"KJ>K>EH.L
M*/F6LQ2U2QZ<G#3;5P1TUDXY^W]5K((*D$2"41'P#IJ'7EH_9**%?,FAK$[M
M+QB_3N1,@Z4E]M([GQ/_`-</]G7.Y72%=J>1CYJ>$9"E^8X1Y$3V/G?D,(B4
MH<P`M57$'W3>)1,(]?;KT3W8W<M=DVJD%.Q5DQ/TMQYTP3MLKO)]#P65?6N2
ME_Y1UCZ40`(#L38$]QV#KOXC]6^^O/:T7"C-13/[=(]$6PMDVP\L*V_F>L`E
MW/@W[?&8N_@&/-SS!_B_+#\/Y#:)=M./,]RVSA(*MZ!Z-Z?N@+W(VQ==NW`(
M-$K(K*H0J(H7RAR91N;EF3<XE-;:C]^1A$VRTT@!PW\B^P/+5L_[HA*&;):?
MF4%$^((BK/\`;2;ES<A>@4!2G[*H`&P%+4K67S!CBG*T@HVI*;ELGJZ2DX.7
M:I/8M^0SIR($=,URF26(!O(0T:O5NXKM!#V..UYPN)436DB:<C/C`!MEK+]U
M&WR$RTC81([:S`J>-(DO=_"2MQ@[VZ[B)X_6_I6V%8WYGJ6M.]?T/`Q\,]D:
M0<KD-4S)VNU*W,<BC%82\MQ$`-JN>RD'-YU2<DHK;`4:&1)-9SZ5BRNZ+:VQ
M&"2;`;7"$"9,QQ'M$O3"H_EWV_;KL99JK+^Y(W%M-'WNJZM%8ZD8NNC^J^I&
MCHEJT19>@W79N$F[MT]!<YW("!C@(`.I9W\+ZU5_*<8"FU<!F=2:`A,Q,ZDD
MTY1!^RTVCCO\TO*W3!!3(_#,%229:2H(V]\P!)=MK)3%]W=^QMTK12-_;;3$
M4LR;TDJDA(UI3KYR1A,,G!46R`NBL3'`VY@,/#D&A?;+V?9'T5S6S4"3-))%
M$I(F1,4T'"#&?&*?<%VU,7(E^T)'4SE/G!9?+?W&-E5VT[KXX7,<FG6EOZBG
MK:&!P=1P/Y+KJ"47B&!%SD%0"-#,E_3,(>X&P!X!H1W=:6=C=MO6P7-6XKF>
M6T4]>D2/M)]W(H\FY*2R)2D)&7Q'7T04_8\JV:M=362';ZN`[.G6N'EX)FFH
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M2/=`JU%WU.W'3<FZC2W8J2HS-5UDEI*D+=5A4,0D9!51`R2$BSB!;J)$$@G`
MQ1VV-OYZ6?P>1:E,MA-.?^&$V<UC7IR2X5?U?QA5^:F;6(=_LONW%??%>XC*
M<N_$9`,;?UA'MXB8IRII*WU6,1*LSG2R<>Q%0&SMB`D]Y0>I@Z><MPEFNSQ%
MZX2G>6T@<0)D@T/0Q%\S?_4Y*TMT3\HK5.8`)H#0CJ(VSD3CC1V1GS!]CH2L
M(M&7I2W^.DQ="H(1^ERBJ@4@I)G&Q[:00'DD^;M).:;*@DH'$3I@;Q`-#W+I
MUGM]#R:+`V^BOWPI:6;#F94W78:Z_O").'P35)DFT19E(V;B#5NBWV2(T20*
M'PY4BE``3!`I0!/;^KTVU"TW+^Y*DRWJ$SU_IX\XL!NRMW4&U5,,G[JBL1]\
MPZ3C;(=YOMZ7GHQLE%R%^65>6BN,9H0$CU"U38D3BEY0A0*5RY9J[""IMS;!
MMJ7XE?\`,<.^+JJV4+*94`Y>@#A%>9RW3ALNVU9?(X4!4_BG/77B3'8<0$T_
M_NQW(A](A3#CI903&*4"F4$:B$=U#?;\=NOETTRRBE#%,!/[O]TP1QS+7\P6
MHSF4$FO'<F'W@L4I!3!0"D(HH78FQ`3,F(\&W+P3`B8`/(>FVHDTZMX_#+[>
M$XG#JTLB:_MZX71?KNAX&8J3KVCJ[NQ!DK()`#2E*T'"R%93*+Q<3&5</VU-
M,GI2K>H`^H*A@-S\0WT:8QUTZD*5(`\Y_A`=_,L(44HU'A^,`+DSW2^V'EGC
ME>NS577$=@>LK<U@C!,:[H*J8`RD\UA7ZT(^C5Y.((1G(-I!,HIJ`8HEV\=&
M[*QN&[EI`V^69S$SI*HG*O,=8B=_=MJ+]XD'ZBDC(2X#2?*<+=K:_P!<FL.Q
MQ@_9.$JB2;3>2-X:2QA7JE!W_P!V^H.)JA=1P)GJ2QEP(^AVX)<@'F)=P$-$
MKZTM[+)*+8H&TGG\2IDG^R(96>3OLA:`/%,]ZA02H)`>\Q+/QWLC;_':SE#V
M?MK3\?3U(T?`Q\6@S8()H)NG2;5('SQR!"E]9TZ<B)E#F$3',.XZ@][?KN;A
MQU_1*I)Z")[B,<BWM4^3JX`I4ZS5+AR$9<@[(4#D-9ZN+1W'A&,S2E70#^+=
MMW*)3':K*-CE9/6"HE,HS?LG`%.DJ38Q#!N&MV5_Y-XV43,U"?4&&]_8[K1U
M2Y32@D>,O"(I_;0J&;P+P&[P4C^*.WTY8>^MP8&GY=PN=TX^(;4NTCJ?6%5<
M0,HY09G2**AAW,<NX^.I]>V*K_(6MDR9)+)=,^8X>ZD0^TN_H<<_DB)OI>#0
MZ!4CIZ_7#2>SO%XXXV886WD*ANK;,;S7H8GO'>.HI*JX1.HY.H*Z77G4V,DJ
ML[,[$T(P?HM12,.Q5$SB'B.@>8Q^<W^2VF;*-):<*^TC2"V)R>/4GS'=WF$]
M.O6&!7OKC$:_-J*]M)7%SK33].UU3$K`.(^0JJ!7;)KOH]RU:/4B'=&])TV<
M+%.!RARW*'LTRQV.[@9NT/(14*'#43%#S'(00R&5Q#K"T.[BG8=)<CUUA:_R
M_MT9"9Q=NM8.7J-"KW.+M\:TMS$SQ797R"]$OG3AY1C5)P4RIG)&J3)<O,1#
MD40#RT1[ZM;NR_S+JDFY<3HD4^$B<Z?O0+[2N;-]_P`BT2X+=*OVM9$'J>1A
M_?(?[)/\G]&H+O<B>23'S4<)%0#YC?UE/_$;YU9"&,[`0%`HJ5?<=#TE3%Z(
M&*J3;<PAOOTUZ.[G^L?[-M6FPHH%BSH)Z(\.4><,9]):]VONOJ2DB]<U,I#S
M09U,?23).1(]!DF"8@)@$JCQN4P;"(=2F.`AX:HUS'7Y'P-N>(02/=%YV68Q
M@8VE;8E^^.9ZP"W<[E8]7M[9D^@\;.3)8[7/.8C9=)8X`-./"!T3,8?$P:=]
MO6-U;92W7<I4%_4)J013=.7L@=G+^V?QK[5LI)065Z$&NTB(JORB(@G=/+<@
M;F%.V]"!L)13.('FVH&$$S['V)RZZL#_`'+=\Q%D.25^\1!_]MV=C]T>&X?W
M50"V+93+?,3([(J&`V4%PDB%.44A,J19V!3!S`!$"B'+Z0U*\@4J[10E6@+A
M]AB+6"3_`*L6H<D>\1)+^:!M1-7"[<IJNA$#OQM+<^DJDE46I5CN6T/*.D(^
M0<G]`P"BW8%2!18Y_<`@]?#56]E7:+3-;R0)I4.'W^.D6=W>PNXP*0!H$?;V
M0@_LE]J#`KN1V1J=S=BM;AQM_J$K"0BZHIFG:@B&[(*745(^@)EBQ<LG`.6"
MR#D"*&+R]\OCU#4_[WR=U9OM9!A"5-)).Z9)"I``4I(C2<5UVE9-W"C8+.T+
MVC2DJE1,R#0\CUAN]S_EJ^UC9JD'M>7+NY=6B:3C53D=S,O4E.QK1,[]P5(S
M9-->'()A65$!*4`$1\M12W[TS;L_(:22!R)D#SX1++GM3';TI4^B1D/;+]7"
M'$=L[MZ8XX`VZJYEC35M45C2=XGD!6"LG/2D;+INDF4>Z;Q2\<[8MDD_3,WD
M#[AON'F'34*[CR]_D3-]M06)Z#0F73I$V[=P=EC4`H<;(IQ/7A.`LR]2'#+N
MQ8M9:PR)&-O,JFAL9[UK`J"$8%4/#%);BHI%43?#[I292(G\%3B8``=&L.M&
M2Q*[1R>\`R%`9B4AZX"9!I6/RH?'R%23/AK,U,9JT;&S@[TM&T<8`E;-]NV@
MDZ^G$`^_C'E[JY261AFY_3V1^/A43E5,"O/W2^[MK2"G'8E149/N2(G0\M#R
M$.'VSDKE"VJH2#.5>,]1'H>['!O,E,Z<",$*KF'T-8NYRM3W(N9$L9!>+_.Y
M:0=)HM:=<+LUF[E=)=,@[I@?B8#>&F^`?=8QIOQ,N?%PTVF@^^,S#++U\;14
M@GX>.LQZX<Q0&,6.=NJ>CZ;H6R%LH2!8L$$&,>6BH(O%BB@FB(K`Y8&745'@
M/)1P)U3CON(AMH5D,YDKAX-.E95/A(#7H/MXP7QV!QK#/G#9MES)X<I_T0B+
MO%VQQLMC?#MN_D6VE"T=<ZL<PJ5?FDJ2IYA"2\A3L;'NADE3GBV[=-RV2<ND
MA-N`\=_+?4TP+ET[AK]5P24A*`-!4*,QXZ:Q#<T+9.:LF[>4]ZIR,]4B4$*P
M,"_S!C<2G64(A@?4X'(*8E0144KZBA3,4XE#F9P0F_01#W>NAEX"GMQ//=^,
M$,<?_L_U?^80]Q1(?3$PJF)R."A@)N`'4.H4R90#QZB3;;SWU#6JK03I(Q8;
M2MCI)TA#/<K*H;N<=HLJ@*@A_%*LM_214,4RYFZ`$$YP`2E*7Q$1U+,"OR\7
M>">K:O=$"[F;\S,,`"FY'WQX.(R@D[ZW<D,1-0VV.=D1)S(*)5`&HQ*;@=4`
M*($V\?/2%^-V+9'4#^P858(:O52_[9Z?MIYPQ#N07CJG'_!C*.[%&)F;UE25
MJY^2AW"*8K"T?O4"1;=^4P`8OK,B.>@A]LFX=-M1_!6BT.I*ZB>G.1,',X^E
M3)0V:RE[OZ(#7M(8&V"M]BA9R[U0T735Q+SWFHB.N-7]RZSBV535`^E*G12D
MWS5![+IO/AD&B[DQ=B<1*/(!^@_DLJXS-MJ:4)D".).L^G@/3$;Q^'5<+"E\
M9\#IR\8,#+?'_%I7'Z\M77'M%:5W&TE:^NIQ*4?TC3I5(LK2G)$&KAN^;,DG
M13*NC`!1,<1Y]`\M)8O(W;]PRIJ845=.L]:?*.'OA]D\2U;VCR5RHD?JI42X
M\S]A$9.*LQ6M?=A+&J]-J(1>1J[%2_[N_=/4_&)`J=Y3L#6AOQ1LS1;!P(",
M(Y%0O,#`!"COY:D.4=#F:#!(DMMOUS(]Q@+B[3R<4IX`E04YI/D#[(E78;96
M6KS$L'1=Y;6U'&SS":BF99QC'NTW#RGI]!NFE*Q$FT3'XAF\;.B&`2J%*)PZ
MATU$<SAS;W"FR"&R:*,Y'CX>KI$KP>82JW"7/F`%)C0"/8Y;92VRQ0LM6-U+
MB5!&QY(F"D3T_`*.D?QRKJ@%L8L9`0$5N9Z_D7+HY`V33/P`VY@VTGB\07KY
ME!!VJ<`F`??I".4S"18OJ011HTF)Z<HB>X20MP<I>UYWCAE8E\RN)<J\-;UP
MM31BI_'`H>GV4RTB7C?B!VZY6)2$4+L13<ON[:M+*DX;)6=P@_$JV4FG7QGR
MB`8UX9#%W#*_E^I!KT'3Q@]NW)VN.V#EEAI8&]2UH9F9J6:HEI&5JZ2N_==D
M9K7<&0D=64:Y9QM;M&#+TYU)8Z:()$]-(Q2[=-1S(=QY-#RDMRV2&HF?&GX0
M;L,?8A(WD`^,OO@YP[%7;'W`26,J4#;F$HA=^])#<B=?<YUZ`F'?PVWT"5WC
MF&5A*16>NT:^J)$WVYC'FRHE)3+F=./&##Q.PHQCPI@*II_&BA$Z#AJ]EVTO
M4Q25#/U,M)3L<5PFT,N]J.6F#`X(F\5`=S!L)NOAH?ELUD<J0WD-Q6G3X0-9
M<@#P$/<7A<?8?QK`)VGDHGGS)@S_`+SV'_:E_-H5M,%X^<1E!V*>Z#666N1-
MW;?6I1+%57?^[%P*0J%A6SF*DE8*I*\J22@W,>+6)(HW=+1$H4YR\_=W$-Q\
M=>BT=VX1>'M+9Q]HN-VS22"HT*42((EPXQYYONT<\K*W-RPP[Y;C[A!"14*6
M3.>[U1K@G8^[TR!?2)"UF)";@00NS4!QX[B)=S&0`1-L/7Z=;9SO:Q9DY<6^
M[Q/X0N,#W0V))8?/H'XPW;MQ]L7N)V@QW[B-"7\IZ7<SUZL<:CH:U3*<JZ0J
M=*1J:0BG[<K!%-X1,&*KE14@`<.77;V:A^4R.%-^P[:/->6EU).TF0`W5-/"
M)#B,3GQ8.M73#OF*2L"<JSE(:^,$/\NGVV,M\$:\R)E<CZ`8TK&5Q1E,15+*
M-)49(CEZPDFKATD*YFC4Z8D*03&*)3;<?'IU$]ZY.RR`M_HWDN;4JG+A,C72
M#G9>)R&.4_\`6,*;"E"6[C\)%*F!0L3VALY:)[RX975';J*:V83OS5%9#4HR
M1S+_`)=E%5S(.BI`EL4I^8=>HC[-22_[AQ"NW!;-W+:KCX_A!,ZBG#C`#&]N
MY5'<"[EZV<3;;4R492)!K*O`1,GN?;2CKR6ZK&V-=PC:<HRN8%]3E0Q+M$AT
MWD?(-S-UBB)S"`*%`VY1VW`P`.J:L[JYM<CYJ9A`),^'V(BT<A9(N<=Y&V:M
MHH-1*('&3G85[AF%=[I6ZG;RGJOJ*D1?24C32E"U",!7E/1[Q8'*<*Y:K-7D
M=($8'`"(B<1W(&VP:N>Q[EP-\RAO)/-I03):5S(]@J.M(JK_`$WFK8J7:LN!
MR0VE($Y^N-:H]M'OP=PRK*=I+*B?N?&T,F[:(2<Q>.93BV$/'MN*AG"$7`)+
M$?N4A2W2.8Q>2FVX:(9#,]CVUBHV"K5;TC\*-P)H>G.&=M@N[W+Q)?%REN8F
M2$RU\8G,X48LL,/,;K;6!C*IG*O)0L:0CB?GG)G+][*+I%!^*9SB8Q8\JF_H
MD$>@:I'*Y93MTIVVMB6U"5%?E%IV>*NFK9*5OD.?\-??&MNYABM*Y?XA71M5
M3C9F2YK%FA6EH)EP46JD1<BDS_CE)NFJR8J*)K?BK)-,1#;?GI_A+UNSR"%.
M'9;DIW<1J)S\./2-YZR<N<<?ITER[`5(#6829=*F4HT/VB,.[K8OX_53.9&"
M+_):^%<R%=7@F$Q!5RNLL0&<+&`Y.?U!;P[81VZ^7AI;O*_9N;M*,8KS&0#,
MIT!)Z](9=F6=XS;+.5;+;NX2"^(":BG7VQ[3N?X`UOEU&6JNW8:M0MIE#CC4
MBM86GJQ8IACI)/<%75*S)DCE6(SD3I%`=@,`\AZ:XP^11:/?2.C_`":B*\)G
MYCX<X=93%*N6C=L_^U(TE6@IQ@0(_,7O71<?^1)OMX4Y.5KZ;=FO<:/KI1G1
M+EPB0K?\<,W/!.'8@J"0&,B`@`!]KKHX_9]O@AYEY)5^F9E74>`@+;'N.K+K
M+H;GK3A00.UT.U?G5?&\6*N7U^:OC*XO_3&0]*3U0TO3LHXCZ"LY9N-:R2KR
M/IYDX:KG?R;Y9PF5X<WI[&13VWW'9_;YO&-XRYL=R6Y(&S]X[B2!34=36!UQ
M@\I_-+>Z#:U)*U;S(4$I"=>,--:XPW>)W>VN61X-K_!HN*$U:4LX62%20"JG
M=64[+MV[J-^$3(FA\)%JB"@*F$!$H;=1VC]S>VKF"%LE:?J`KY1Z?9!JSQ]X
MWE2\MM09VZF7ZA]T-@/R](_I@!E`3W(7IU.0AQ+]8&VU&&I;D;J)XQ,3JHB%
M/YJXMW=O%G#V\[UT-#L7=%6"KJIIBXCUP].F+".E&J8%5*B")@45.*8@0-^I
MQVZ!UT>QUS;L6=PVM<EK20!Z.'C$:RUE<7.09>;;)0DIF?`\?"!HS5Q4S.LE
MFN/<-P1IRF[EU%6MN8JVM[K.5))N(X*JAX-P9Q'.811!HY3!VF8I3<C[<3;Z
M69OK1S'FU>4`L*$NH'$=1QAE>V%_]:E]AI13M.G7@8WU81SF)FI;J^=L<Z<9
M:6LK:.NZ,/1<534?4CB=GWJ,JB\;NW:QSQC!+BR5*DL'7ITTY?3C+0)7:.A3
MP5/F#I,'34:=8<I8R+H_C-*D1T]!'IUZ0!UHJ<[M_;!@@L!;ZS%.YL8[4ZY4
M2M5/LY]>`KRF8-9PHHC`R:#AC)-E6K)(2D((*>`:<KM\%D0''7TMGD09^D>Z
M.T*RMJ-K3"U>!$=HKVQ_<\[F%+5)2&25)0F)>.)HE_(+6IIF:<2MQ[HS[-C(
M!&051R0,X]I%TP]>*I`J!"JF$";[:5MAV_BWVEI>;<`5+0T!H23P`G/B3`S(
M.9V\9<067=Z@*3%92_"#Z[6&-=9XJX%T58"^\-34--TV_K%M-PR+TKJ`_+LY
M**_A[9VY?IMR*)NH\2$-N`;FZ;:"9^_9=S"7<<L+:`0`I/`@GF.$','9%&'4
MS?IV.G?1764M#Q@5KJ]D&F6USY>[N%62=U,,9^KG`2M10-LW#=[1SR25_P"*
M_:13A<C9J91,XAL`&`=]]]$6NXF"V;;(@*<-4JXR'[I_&!#V'N$N)<L4E320
M0J7`\`:QV2TW:0M]9JJ7F2^7V0%Q,LJVMW$R531$S=IVW;4K3*T:V7=+RJ<*
MFL>/7<`@GM[XE`-@\=(_S!=Q>-)L)I47$R.A!\*^N$%XTLV;QO1)/EJUXQU7
ML1Q):WM%F#>DT,S4H3(;*RZ554<=1`R:%0THB^<P*+LJ1B`D,4Z0:<$.(;"4
M-/\`N[(O.W-N"2"VWST,STC?:N)M38O)44_$[/342'6->U3A;GAV[;SW"NKV
MY6M,79QVNM/.JUK3&"L)!U'+4W5DH=124<T(X0;ND6;-P<XG,`DZ&Z;#XZ0L
MK[%7C1:R"DMJ_49SU-09?:<=7V&O+=>ZR2I8Z#PZQDJ&^G>YRI9+VKH/%.F\
M0XV:1-&U#=*MZP7?OF#%T06<FM!-F<&4"N`;+'.@(F_K@7?2CMMVPT"^W<H<
M6D3"3,S(J`)2J=(29;[A(\DM.(0JA-`)&GJ@\K<V%OMA!BK;BTEE9>=OK7[6
MJ',O754US('D7SIQ.G%6:=I*"!#$:(JJ#Z!=_=`-`T/65]?;[K8TR3J:RIZ.
M,2!EB]L+$(:W./`"@D./IX0P+\3K_P#]<C^GUZ'[+;]2?;!/<_\`I5&R3%+N
M/5+Q'Q$F_CY]=,I/<)RC2DJW&HUZ1;Q+[4OVD_GUDG^OMC6U7,>R+#D4$4Q(
M=$"`;[T!X=2]?UZ7;)"2')E?#6'+4PBO..2E#F84Q2V$0X<#)AL/7?<`'J(Z
MZG0;I^F<*Q9Q;\_?!+U=@W$RB7+Z.@GY:Y<)*1^F?*-&,ABDX^\!13Y!L4%"
M![VX;;&$P!OO].D8U%'*3B/J^F*?'H0QB<Q#R`IQ,``.WTZR,B@*IP\#')TX
M`BH4G'PZF,!R@8-O'J.LC(KB/M+_`)R?[VLC(M.0_P#S1*(?WCD#K_K&#61D
M<E+T#CPVVZ;')MM]&QMM9&1P!2\C<0+ZFP<C`H3P\MR@;?P^C2Z2=@G\OA&Q
M%`4.74[;?;J'W?+?K]?AMKJ9E0*]L;BX"D^UP'H'VR;?5[P:2<,XT8YXD^SP
M`?\`&3P_S:3C46'(<2CQ$H&Z;>^3VAO]KV:R,BBE(!!!8"F'B._WB8=-A\Q.
M`;:R,C(!0XAMZ94]O!0Q#AM^O<P:R,C$0BO$>*B`I;=`3X`7]VP:<E2)U"MW
M6.HL.1OZNZOPX$XAP]0Z(^]L'@`F'SUN:ME)SGR,92+TB"`&Y"D8?,2&(!?[
MNP;AL''7*R)5GMZQL%F8^7S.-*P*V9EI:1O9CI<RVM;7+<6@INIXMHT>7%C*
MHCZ7D::?)OVRL4^;R\G)1<:S$KPA0^\7(*F_$-Q';3O'O6C5PDK2A22:S$P*
MBM`232E(:9!+BVSY-#+G+@><H3'2-%=\?$I@A2MI:BLGGG9]HDB2F9Z<JFGZ
M9N&-/D3`D<G+2\VK%Q;]7X;8WJE=JD.'VAU+">T;[REW[AMW4I,DALS/I`K+
MI.(8^>Y[<*1C6@\A1^(ET"1Y:\1'H+LVQ[MN9-(2=+YF5=9'`O$DA"/+M.F-
MP*7<5+,4:B<IY&'6JUB_<4]",'2"8E477?H)E(<=S:;M/X:RNPK%A5PN8D-B
MMT^E)^,:>M\Q=6>W)D,ID9_Q$REXE4M(>EB11MBJ!L!;&D<9)JBZDL7!4VA'
M4'.T!5<+6-+2,:V$Q%';*HH%_(Q$JX<//4,LLW75(943>\.HQE[S(7&2/U+.
MQL@F9!214R`!`)'642/"6-G:VDV'PXNDQ,*K(3J"13Q@E>/]H-P\P*H0IOJ'
MF&VA\&8Q+$-[O,BQR;AL"3@J?'KXG$52\BAUW#KOK(R/(("/7AZ13>T3)GZ?
24(^>LC(\CI[2?L#^?61D?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
